FDA Compounding Summit With States: Strategic Step Forward Or 50 More Cooks?
This article was originally published in The Pink Sheet Daily
FDA has yet to define where it would like to draw the line between federal and state oversight of compounding pharmacies, but the Dec. 19 could be the first step to consensus on the responsibilities that each regulator should take.
You may also be interested in...
As meningitis outbreak widens, FDA and members of Congress are calling for clarification of what jurisdiction the agency has over pharmacies, but agency officials are stopping short of asking for clear new authorities.
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.